| Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. Gupta M., Maurer M.J., Wellik L.E., Law M.E., Han J.J., Ozsan N., Micallef I.N., Dogan A., Witzig T.E.
Blood 120:4400-4406(2012) · Mapped (14) |
| Mast cells orchestrate type 2 immunity to helminths through regulation of tissue-derived cytokines. Hepworth M.R., Danilowicz-Luebert E., Rausch S., Metz M., Klotz C., Maurer M., Hartmann S.
Proc. Natl. Acad. Sci. U.S.A. 109:6644-6649(2012) · Mapped (4) |
| Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Gupta M., Han J.J., Stenson M., Maurer M., Wellik L., Hu G., Ziesmer S., Dogan A., Witzig T.E.
Blood 119:2844-2853(2012) · Mapped (13) |
| LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. Cerhan J.R., Natkunam Y., Morton L.M., Maurer M.J., Asmann Y., Habermann T.M., Vasef M.A., Cozen W., Lynch C.F., Allmer C. et al.
Leuk. Lymphoma 53:1105-1112(2012) · Mapped (1) |
| T cell killing by tolerogenic dendritic cells protects mice from allergy. Luckey U., Maurer M., Schmidt T., Lorenz N., Seebach B., Metz M., Steinbrink K.
J. Clin. Invest. 121:3860-3871(2011) · Mapped (4) |
| Design of Factor XIII V34X activation peptides to control ability to interact with thrombin mutants. Jadhav M.A., Lucas R.C., Goldsberry W.N., Maurer M.C.
Biochim. Biophys. Acta 1814:1955-1963(2011) · Mapped (12) |
| Role of calcium in the conformational dynamics of factor XIII activation examined by hydrogen-deuterium exchange coupled with MALDI-TOF MS. Woofter R.T., Maurer M.C.
Arch. Biochem. Biophys. 512:87-95(2011) · Mapped (4) |
| Evidence that the endothelin A receptor can enhance IgE-dependent anaphylaxis in mice. Metz M., Schafer B., Tsai M., Maurer M., Galli S.J.
J. Allergy Clin. Immunol. 128:424-6.e1(2011) · Mapped (2) |
| Interference with ER-alpha enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells. Wesierska-Gadek J., Gritsch D., Zulehner N., Komina O., Maurer M.
J. Cell. Biochem. 112:1103-1117(2011) · Mapped (58) |
| Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS). Bhuiyan T., Helmke S., Patel A.R., Ruberg F.L., Packman J., Cheung K., Grogan D., Maurer M.S.
Circ Heart Fail 4:121-128(2011) · Mapped (6) |
| IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. Eller K., Wolf D., Huber J.M., Metz M., Mayer G., McKenzie A.N., Maurer M., Rosenkranz A.R., Wolf A.M.
J. Immunol. 186:83-91(2011) · Mapped (5) |
| Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis. Doerck S., Gobel K., Weise G., Schneider-Hohendorf T., Reinhardt M., Hauff P., Schwab N., Linker R., Maurer M., Meuth S.G. et al.
PLoS ONE 5:e15478-e15478(2010) · Mapped (19) |
| Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma. Durnick D.K., Law M.E., Maurer M.J., Natkunam Y., Levy R., Lossos I.S., Kurtin P.J., McPhail E.D.
Am. J. Clin. Pathol. 134:278-281(2010) · Mapped (1) |
| Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. Hannigan A., Smith P., Kalna G., Lo Nigro C., Orange C., O'Brien D.I., Shah R., Syed N., Spender L.C., Herrera B. et al.
J. Clin. Invest. 120:2842-2857(2010) · Mapped (12) |
| Immature mast cells exhibit rolling and adhesion to endothelial cells and subsequent diapedesis triggered by E- and P-selectin, VCAM-1 and PECAM-1. Dudeck A., Leist M., Rubant S., Zimmermann A., Dudeck J., Boehncke W.H., Maurer M.
Exp. Dermatol. 19:424-434(2010) · Mapped (13) |
| B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Dillon S.R., Harder B., Lewis K.B., Moore M.D., Liu H., Bukowski T.R., Hamacher N.B., Lantry M.M., Maurer M., Krejsa C.M. et al.
Arthritis Res. Ther. 12:R48-R48(2010) · Mapped (14) |
| Effects of introducing fibrinogen Aalpha character into the factor XIII activation peptide segment. Jadhav M.A., Isetti G., Trumbo T.A., Maurer M.C.
Biochemistry 49:2918-2924(2010) · Mapped (6) |
| Inherited determinants of ovarian cancer survival. Goode E.L., Maurer M.J., Sellers T.A., Phelan C.M., Kalli K.R., Fridley B.L., Vierkant R.A., Armasu S.M., White K.L., Keeney G.L. et al.
Clin. Cancer Res. 16:995-1007(2010) · Mapped (1) |
| Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Fine B., Hodakoski C., Koujak S., Su T., Saal L.H., Maurer M., Hopkins B., Keniry M., Sulis M.L., Mense S. et al.
Science 325:1261-1265(2009) · Mapped (6) |
| A non-reactive glutamine residue of alpha2-antiplasmin promotes interactions with the factor XIII active site region. Cleary D.B., Doiphode P.G., Sabo T.M., Maurer M.C.
J. Thromb. Haemost. 7:1947-1949(2009) · Mapped (5) |
| Biophysical investigation of GpIbalpha binding to thrombin anion binding exosite II. Sabo T.M., Maurer M.C.
Biochemistry 48:7110-7122(2009) · Mapped (7) |
| Engineering of bottlenecks in Rhizopus oryzae lipase production in Pichia pastoris using the nitrogen source-regulated FLD1 promoter. Resina D., Maurer M., Cos O., Arnau C., Carnicer M., Marx H., Gasser B., Valero F., Mattanovich D., Ferrer P.
N Biotechnol 25:396-403(2009) · Mapped (2) |
| Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants. Kroner A., Schwab N., Ip C.W., Ortler S., Gobel K., Nave K.A., Maurer M., Martini R., Wiendl H.
Am. J. Pathol. 174:2290-2299(2009) · Mapped (2) |
| Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands. Mrabet-Dahbi S., Metz M., Dudeck A., Zuberbier T., Maurer M.
Exp. Dermatol. 18:437-444(2009) · Mapped (4) |
| Matrix metalloproteinase-9: a novel biomarker for monitoring disease activity in patients with chronic urticaria patients? Altrichter S., Boodstein N., Maurer M.
Allergy 64:652-656(2009) · Mapped (7) |
